Mesoblast Announces Planned Board Leadership Transition, Appointing New Chair and Audit Committee Chair

summarizeSummary

Mesoblast Limited announced a planned transition in its Board leadership, with Ms. Jane Bell stepping down as Chair and Mr. Philip Facchina appointed as the new non-executive Chair, alongside Ms. Lyn Cobley as Audit and Risk Committee Chair.

check_boxKey Events

• Board Chair Transition

  Ms. Jane Bell retired from her role as Chair but will remain on the Board as a non-executive director, following a period of significant company transformation.

• New Non-Executive Chair Appointed

  Mr. Philip Facchina, a board member since March 2021 with over forty years of experience in corporate strategy, finance, and business development, has been unanimously appointed as the new non-executive Chair.

• New Audit and Risk Committee Chair

  Ms. Lyn Cobley, who joined the board in April 2025, was appointed as Chair of the Audit and Risk Committee, bringing extensive corporate finance and governance expertise.

• Strategic Board Evolution

  These changes are part of a periodic review of Board composition, aligning with the company's evolution into a revenue-generating commercial company and its commitment to sound governance.

auto_awesomeAnalysis

The changes in Mesoblast's Board leadership, including the appointment of a new non-executive Chair and Audit and Risk Committee Chair, are presented as a planned evolution to support the company's transition to a revenue-generating commercial entity. While Ms. Jane Bell retires as Chair, she remains a non-executive director, indicating an orderly transition rather than an abrupt departure. The new appointees bring relevant experience in corporate strategy, finance, and governance, which could strengthen the board's oversight as the company focuses on commercial delivery and shareholder value.